Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...
Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...
We recently compiled a list of the Jim Cramer Discusses These 12 Stocks, Elon Musk & President Trump. In this article, we are ...
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
Saint John's High School junior Lily Dunlap told ABC13 that her faith in God, her family, and basketball got her through her battle with cancer, leading her to win Naismith Courage Award.
The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and middle-income countries, where access to care and new therapies is often limited.
Patrik Jonsson is the president of Eli Lilly & Co.'s cardiometabolic health unit. "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices," at 9:48 a.m. ET, incorrectly said his ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.